
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc has demonstrated robust quarterly growth in prescriptions for Auvelity, achieving an 8% increase despite a stagnant overall market, suggesting effective marketing and sales strategies. The company's strategic expansion of its sales force to 600 representatives is anticipated to enhance its sales capabilities and facilitate the execution of a significant market opportunity projected at $1.6 billion by 2035. Additionally, the potential approval of AXS-05 in Alzheimer's Disease is expected to further bolster the company's revenue prospects, positioning Axsome for accelerated commercial momentum and potential cash flow positivity by mid-2026.
Bears say
The negative outlook on Axsome Therapeutics’s stock is largely attributed to several key risks, including potential setbacks in clinical trials for major pipeline candidates, which could impede their development and market access. There are concerns regarding the company's ability to secure timely approvals for its products, as well as competition and market penetration challenges, particularly in a crowded space where innovative differentiation is lacking. Additionally, significant financial risks exist due to high research and development costs, potential for long-term dilution, and the historical difficulties the company has faced with regulatory applications.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares